Robeco Schweiz AG Reduces Stock Position in Boston Scientific Corporation (NYSE:BSX)

Robeco Schweiz AG lowered its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 9.9% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 102,769 shares of the medical equipment provider's stock after selling 11,303 shares during the quarter. Robeco Schweiz AG's holdings in Boston Scientific were worth $10,367,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Investment Management Corp VA ADV acquired a new stake in Boston Scientific during the 4th quarter worth about $25,000. Colonial Trust Co SC raised its stake in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 260 shares during the last quarter. Sunbeam Capital Management LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $26,000. Ameriflex Group Inc. purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $31,000. Finally, Fourth Dimension Wealth LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on BSX shares. Evercore ISI lifted their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Leerink Partners started coverage on Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. BTIG Research reiterated a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, April 23rd. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Needham & Company LLC restated a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a research note on Wednesday, May 28th. Twenty-two equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average price target of $116.09.

Boston Scientific Trading Down 0.7%

BSX traded down $0.70 during trading hours on Friday, reaching $103.16. The company's stock had a trading volume of 5,890,147 shares, compared to its average volume of 6,701,002. The stock has a market cap of $152.62 billion, a PE ratio of 75.30, a P/E/G ratio of 2.70 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. Boston Scientific Corporation has a fifty-two week low of $71.88 and a fifty-two week high of $107.53. The business's 50-day moving average is $103.42 and its 200-day moving average is $100.53.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm's quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.56 earnings per share. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president owned 18,705 shares of the company's stock, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $106.97, for a total value of $5,348,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $19,077,243.74. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 461,970 shares of company stock valued at $47,755,193. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.